Loading…
ACOG
Alpha Cognition Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 02074J501
$9.16-5.91%Price as of Aug 29, 18:41 UTC · updated once a day, after the close
Key metrics
- Market cap
- $199.49M
- P/E
- —
- Forward P/E
- —
- P/B
- 3.8x
- Dividend yield
- —
- Payout
- —
- EPS
- -$0.96
- ROE
- -49.53%
- Profit margin
- -137.70%
- Revenue growth
- +267.60%
- Beta
- 2.23
- 52-week high
- $10.14
- 52-week low
- $4.50
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▲ +27.9% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 2 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 |
|---|---|---|---|
| Year-end price | $6.50 | $5.89 | |
| P/S | — | 13.8x | — |
| P/B | — | 2.3x | 2.4x |
| EPS | -$1.18 | -$2.04 | |
| Profit margin | — | -202.24% | — |
| ROE | — | -33.06% | -37.83% |
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ARMPArmata Pharmaceuticals, Inc. | $5.37 | — | — | — | — | $199.67M |
| PDEXPro Dex Inc | $62.56 | 17.9x | 4.4x | — | 29.83% | $199.72M |
| DTILPrecision Biosciences Inc | $7.19 | — | 4.2x | — | -135.15% | $198.46M |
| FOCLEdap Tms SA | $4.31 |
About the company
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.
- 71
- Grapevine, United States
Company description provided by Yahoo Finance.